Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10973905 | PMC |
| http://dx.doi.org/10.2337/dc23-2420 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comment on Kutz et al. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. Diabetes Care 2023;46:2004-2014.
Diabetes Care
April 2024
Foundation for Diabetes Research in Older People (fDROP), Droitwich Spa, London, U.K.
Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.
Kidney Int
January 2023
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
The novel nonsteroidal mineralocorticoid receptor antagonist finerenone has been shown to reduce the risk of kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. In this issue of Kidney International, Bakris et al. present new data on the kidney efficacy of finerenone across subgroups of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, as well as safety data.
View Article and Find Full Text PDFComparison of characteristics, predictors and outcomes between the first and second COVID-19 waves in a tertiary care centre in Switzerland: an observational analysis.
Swiss Med Wkly
August 2021
Department of Medicine, Kantonsspital Aarau, Switzerland / Medical Faculty, University of Basel, Switzerland.
Aim Of The Study: To compare admission characteristics, predictors and outcomes of patients with confirmed coronavirus disease 2019 (COVID-19) hospitalised in a tertiary care hospital in Switzerland during the first and second waves of the pandemic.
Methods: This retrospective observational analysis included adult patients with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection confirmed by a real-time reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen test and hospitalised at the Cantonal Hospital Aarau from 26 February to 30 April 2020 (first wave) and from 1 October to 31 December 2020 (second wave). The primary endpoint was all-cause in-hospital mortality.
Response to Charlier et al.: Climate-Disease Feedbacks Mediated by Livestock Methane Emissions Are Plausible.
Trends Ecol Evol
July 2021
Department of Biology, Washington University in St. Louis, St. Louis, MO 63130, USA.
Symptomatic mucosal involvement in pachyonychia congenita: challenges in infants and young children.
Br J Dermatol
March 2020
Department of Dermatology, University of Utah, UT, U.S.A.
Background: Pachyonychia congenita (PC) is a rare autosomal dominant genodermatosis caused by a mutation in any one of five keratin genes (KRT6A, KRT6B, KRT6C, KRT16 or KRT17). Characteristic features of PC are painful palmoplantar keratoderma, variable nail dystrophy, cysts, follicular hyperkeratosis and often oral leukokeratosis. Although oral leukokeratosis can go unnoticed, mucosal involvement of the oral cavity and upper airways can manifest with pain during feeding, hoarseness, stridor and, occasionally, life-threatening obstruction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!